Rep. Lisa C. McClain Sells Off Shares of Humana Inc. (NYSE:HUM)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Humana Inc. (NYSE:HUM). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Humana stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Humana Price Performance

HUM traded down $0.42 on Friday, reaching $245.57. The stock had a trading volume of 161,929 shares, compared to its average volume of 1,756,902. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $29.54 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The firm has a 50-day moving average of $263.32 and a 200-day moving average of $256.70.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. During the same period last year, the firm posted $4.16 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. Humana’s payout ratio is currently 33.18%.

Institutional Investors Weigh In On Humana

Several institutional investors and hedge funds have recently made changes to their positions in the business. Cary Street Partners Investment Advisory LLC lifted its stake in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Humana in the 2nd quarter valued at $32,000. Mather Group LLC. bought a new stake in shares of Humana in the 3rd quarter valued at $34,000. Zions Bancorporation National Association UT acquired a new position in shares of Humana during the 1st quarter valued at $37,000. Finally, AlphaCore Capital LLC bought a new position in Humana during the second quarter worth $39,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HUM. Evercore ISI began coverage on shares of Humana in a research report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price target for the company. Truist Financial lowered their target price on Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Morgan Stanley cut their target price on Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a report on Thursday, July 31st. Piper Sandler decreased their price target on Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research note on Thursday, July 31st. Finally, Wells Fargo & Company raised their price objective on Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 7th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $295.94.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.